CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion

Biochemical and Biophysical Research Communications

Volumn 418, Issue 1, 2012, Pages 104-109

  Yanagi, Hiroko ^a   Wang, Lei ^a   Nishihara, Hiroshi ^a   Kimura, Taichi ^a   Tanino, Mishie ^a   Yanagi, Teruki ^a   Fukuda, Satoshi ^a   Tanaka, Shinya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

C3G; CRK; CRKL; Head and neck squamous cell carcinoma; Tumorigenesis

Indexed keywords

COLLAGEN; CRK LIKE PROTEIN; FIBRONECTIN; INTEGRIN; POLYLYSINE; PROTEIN P130; RAP1 PROTEIN; SHORT HAIRPIN RNA;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL ASSAY; CELL CULTURE; CELL GROWTH; CELL MOTILITY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; WOUND HEALING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; NUCLEAR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84862826343     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.142     Document Type: Article

References (29)

1. Mayer B.J., Hamaguchi M., Hanafusa H. A novel viral oncogene with structural similarity to phospholipase C. Nature 1988, 332:272-275.
2. Matsuda M., Tanaka S., Nagata S., Kojima A., Kurata T., Shibuya M. Two species of human CRK cDNA encode proteins with distinct biological activities. Mol. Cell Biol. 1992, 12:3482-3489.
3. ten Hoeve J., Morris C., Heisterkamp N., Groffen J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene 1993, 8:2469-2474.
4. Feller S.M., Knudsen B., Hanafusa H. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 1994, 13:2341-2351.
5. Hasegawa H., Kiyokawa E., Tanaka S., Nagashima K., Gotoh N., Shibuya M., Kurata T., Matsuda M. DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane. Mol. Cell Biol. 1996, 16:1770-1776.
6. Tanaka S., Morishita T., Hashimoto Y., Hattori S., Nakamura S., Shibuya M., Matuoka K., Takenawa T., Kurata T., Nagashima K., et al. C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. Proc. Natl. Acad. Sci. USA 1994, 91:3443-3447.
7. Gotoh T., Hattori S., Nakamura S., Kitayama H., Noda M., Takai Y., Kaibuchi K., Matsui H., Hatase O., Takahashi H., et al. Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol. Cell Biol. 1995, 15:6746-6753.
8. Gotoh T., Niino Y., Tokuda M., Hatase O., Nakamura S., Matsuda M., Hattori S. Activation of R-Ras by Ras-guanine nucleotide-releasing factor. J. Biol. Chem. 1997, 272:18602-18607.
9. Kiyokawa E., Hashimoto Y., Kobayashi S., Sugimura H., Kurata T., Matsuda M. Activation of Rac1 by a Crk SH3-binding protein, DOCK180. Genes Dev. 1998, 12:3331-3336.
10. Linghu H., Tsuda M., Makino Y., Sakai M., Watanabe T., Ichihara S., Sawa H., Nagashima K., Mochizuki N., Tanaka S. Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS. Oncogene 2006, 25:3547-3556.
11. Wang L., Tabu K., Kimura T., Tsuda M., Linghu H., Tanino M., Kaneko S., Nishihara H., Tanaka S. Signaling adaptor protein Crk is indispensable for malignant feature of glioblastoma cell line KMG4. Biochem. Biophys. Res. Commun. 2007, 362:976-981.
12. Watanabe T., Tsuda M., Makino Y., Ichihara S., Sawa H., Minami A., Mochizuki N., Nagashima K., Tanaka S. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines. Mol. Cancer Res. 2006, 4:499-510.
13. Yamada S., Yanamoto S., Kawasaki G., Rokutanda S., Yonezawa H., Kawakita A., Nemoto T.K. Overexpression of CRKII increases migration and invasive potential in oral squamous cell carcinoma. Cancer Lett. 2011, 303:84-91.
14. Nichols G.L., Raines M.A., Vera J.C., Lacomis L., Tempst P., Golde D.W. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994, 84:2912-2918.
15. ten Hoeve J., Kaartinen V., Fioretos T., Haataja L., Voncken J.W., Heisterkamp N., Groffen J. Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res. 1994, 54:2563-2567.
16. Senechal K., Halpern J., Sawyers C.L. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J. Biol. Chem. 1996, 271:23255-23261.
17. Kim Y.H., Kwei K.A., Girard L., Salari K., Kao J., Pacyna-Gengelbach M., Wang P., Hernandez-Boussard T., Gazdar A.F., Petersen I., Minna J.D., Pollack J.R. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene 2010, 29:1421-1430.
18. Wang J., Che Y.L., Li G., Liu B., Shen T.M., Wang H., Linghu H. Crk and CrkL present with different expression and significance in epithelial ovarian carcinoma. Mol. Carcinog. 2011, 50:506-515.
19. Forastiere A., Koch W., Trotti A., Sidransky D. Head and neck cancer. N. Engl. J. Med. 2001, 345:1890-1900.
20. Pignon J.P., Bourhis J., Domenge C., Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355:949-955.
21. Cooper J.S., Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., Kish J.A., Kim H.E., Cmelak A.J., Rotman M., Machtay M., Ensley J.F., Chao K.S., Schultz C.J., Lee N., Fu K.K. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004, 350:1937-1944.
22. Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefebvre J.L., Greiner R.H., Giralt J., Maingon P., Rolland F., Bolla M., Cognetti F., Bourhis J., Kirkpatrick A., van Glabbeke M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004, 350:1945-1952.
23. Nishihara H., Maeda M., Oda A., Tsuda M., Sawa H., Nagashima K., Tanaka S. DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines. Blood 2002, 100:3968-3974.
24. Tabu K., Ohba Y., Suzuki T., Makino Y., Kimura T., Ohnishi A., Sakai M., Watanabe T., Tanaka S., Sawa H. Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA. Mol. Cancer Res. 2007, 5:1099-1109.
25. Tsuda M., Tanaka S., Sawa H., Hanafusa H., Nagashima K. Signaling adaptor protein v-Crk activates Rho and regulates cell motility in 3Y1 rat fibroblast cell line. Cell Growth Differ. 2002, 13:131-139.
26. Nishihara H., Tanaka S., Tsuda M., Oikawa S., Maeda M., Shimizu M., Shinomiya H., Tanigami A., Sawa H., Nagashima K. Molecular and immunohistochemical analysis of signaling adaptor protein Crk in human cancers. Cancer Lett. 2002, 180:55-61.
27. Fioretos T., Heisterkamp N., Groffen J., Benjes S., Morris C. CRK proto-oncogene maps to human chromosome band 17p13. Oncogene 1993, 8:2853-2855.
28. Reedquist K.A., Ross E., Koop E.A., Wolthuis R.M., Zwartkruis F.J., van Kooyk Y., Salmon M., Buckley C.D., Bos J.L. The small GTPase, Rap1, mediates CD31-induced integrin adhesion. J. Cell Biol. 2000, 148:1151-1158.
29. Posern G., Weber C.K., Rapp U.R., Feller S.M. Activity of Rap1 is regulated by bombesin, cell adhesion, and cell density in NIH3T3 fibroblasts. J. Biol. Chem. 1998, 273:24297-24300.